<DOC>
	<DOCNO>NCT00290342</DOCNO>
	<brief_summary>DTPa IPV vaccine recommend immunization infant Korea . The use combination vaccine simplifies routine paediatric vaccination . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Evaluation Immunogenicity , Safety Reactogenicity Combined DTPa-IPV Vaccine Healthy Infants</brief_title>
	<detailed_description>Participants Phase IIIb study either receive GSK Biologicals ' combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus ( DTPa-IPV ) vaccine co-administration GSK Biologicals ' combined diphtheria-tetanus-acellular pertussis ( DTPa ) vaccine Sanofi-Pasteurs ' inactivated poliovirus vaccine . Vaccines group administer 2 , 4 6 month age . Two blood sample collect course study : prior vaccination one month third vaccine dose .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>Inclusion criterion : Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 8 12 week ( 5690 day ) age time first vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Administration vaccine within 30 day ( i.e.30 day 1 day ) first dose study vaccine . Planned administration/ administration vaccine foreseen study protocol study period ( i.e . Day 0 Month 7 ) , exception Bacille CalmetteGu√©rin ( BCG ) vaccine , hepatitis B vaccine , pneumococcal vaccine , flu vaccine Hib vaccine . Planned administration/ administration vaccine foreseen study protocol ( i.e . BCG vaccine , hepatitis B vaccine , pneumococcal , flu vaccine Hib vaccine ) period 30 day one week study vaccine dose . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous vaccination diphtheria , tetanus , pertussis and/or poliovirus disease . History diphtheria , tetanus , pertussis and/or poliovirus disease . Known exposure diphtheria , tetanus , pertussis and/or poliovirus study period . Any anaemia/ thrombocytopenia blood clot lead prohibition intramuscular injection . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>